1,25-Dihydroxyvitamin D stimulation test for osteoblast function in normal and osteoporotic postmenopausal women

R. J. Duda; R. Kumar; K. I. Nelson; A. R. Zinsmeister; K. G. Mann; B. L. Riggs

doi:10.1172/JCI112944

1,25-Dihydroxyvitamin D stimulation test for osteoblast function in normal and osteoporotic postmenopausal women

R. J. Duda, R. Kumar, K. I. Nelson, A. R. Zinsmeister, K. G. Mann, B. L. Riggs

Research output: Contribution to journal › Article › peer-review

53 Scopus citations

Abstract

The cause of bone loss in postmenopausal osteoporosis - decreased bone formation or increased bone resorption - is controversial. Synthesis of bone-Gla protein (BGP), a specific osteoblast product, is stimulated by 1,25-dihydroxyvitamin D₃ [1,25(OH)₂D] in vitro. Thus, increases in serum BGP levels during 1,25(OH)₂D administration might provide a useful dynamic index of osteoblast function. We compared 14 postmenopausal osteoporotic women with 12 age-matched postmenopausal normal women before and during 6 d of 1,25(OH)₂D administration (2.0 μg/d). Serum BGP levels were similar at baseline and increased during treatment in both groups (P < 0.001). However, trend analysis showed a greater (P < 0.01) increase in the osteoporotic women. These data do not support the hypothesis that defective osteoblast function is the major cause of bone loss in postmenopausal osteoporosis.

Original language	English (US)
Pages (from-to)	1249-1253
Number of pages	5
Journal	Journal of Clinical Investigation
Volume	79
Issue number	4
DOIs	https://doi.org/10.1172/JCI112944
State	Published - 1987

ASJC Scopus subject areas

General Medicine

Access to Document

10.1172/JCI112944

Cite this

@article{c7a07563730c435cb76bb0bfdf354b24,

title = "1,25-Dihydroxyvitamin D stimulation test for osteoblast function in normal and osteoporotic postmenopausal women",

abstract = "The cause of bone loss in postmenopausal osteoporosis - decreased bone formation or increased bone resorption - is controversial. Synthesis of bone-Gla protein (BGP), a specific osteoblast product, is stimulated by 1,25-dihydroxyvitamin D3 [1,25(OH)2D] in vitro. Thus, increases in serum BGP levels during 1,25(OH)2D administration might provide a useful dynamic index of osteoblast function. We compared 14 postmenopausal osteoporotic women with 12 age-matched postmenopausal normal women before and during 6 d of 1,25(OH)2D administration (2.0 μg/d). Serum BGP levels were similar at baseline and increased during treatment in both groups (P < 0.001). However, trend analysis showed a greater (P < 0.01) increase in the osteoporotic women. These data do not support the hypothesis that defective osteoblast function is the major cause of bone loss in postmenopausal osteoporosis.",

author = "Duda, {R. J.} and R. Kumar and Nelson, {K. I.} and Zinsmeister, {A. R.} and Mann, {K. G.} and Riggs, {B. L.}",

year = "1987",

doi = "10.1172/JCI112944",

language = "English (US)",

volume = "79",

pages = "1249--1253",

journal = "Journal of Clinical Investigation",

issn = "0021-9738",

publisher = "The American Society for Clinical Investigation",

number = "4",

}

TY - JOUR

T1 - 1,25-Dihydroxyvitamin D stimulation test for osteoblast function in normal and osteoporotic postmenopausal women

AU - Duda, R. J.

AU - Kumar, R.

AU - Nelson, K. I.

AU - Zinsmeister, A. R.

AU - Mann, K. G.

AU - Riggs, B. L.

PY - 1987

Y1 - 1987

N2 - The cause of bone loss in postmenopausal osteoporosis - decreased bone formation or increased bone resorption - is controversial. Synthesis of bone-Gla protein (BGP), a specific osteoblast product, is stimulated by 1,25-dihydroxyvitamin D3 [1,25(OH)2D] in vitro. Thus, increases in serum BGP levels during 1,25(OH)2D administration might provide a useful dynamic index of osteoblast function. We compared 14 postmenopausal osteoporotic women with 12 age-matched postmenopausal normal women before and during 6 d of 1,25(OH)2D administration (2.0 μg/d). Serum BGP levels were similar at baseline and increased during treatment in both groups (P < 0.001). However, trend analysis showed a greater (P < 0.01) increase in the osteoporotic women. These data do not support the hypothesis that defective osteoblast function is the major cause of bone loss in postmenopausal osteoporosis.

AB - The cause of bone loss in postmenopausal osteoporosis - decreased bone formation or increased bone resorption - is controversial. Synthesis of bone-Gla protein (BGP), a specific osteoblast product, is stimulated by 1,25-dihydroxyvitamin D3 [1,25(OH)2D] in vitro. Thus, increases in serum BGP levels during 1,25(OH)2D administration might provide a useful dynamic index of osteoblast function. We compared 14 postmenopausal osteoporotic women with 12 age-matched postmenopausal normal women before and during 6 d of 1,25(OH)2D administration (2.0 μg/d). Serum BGP levels were similar at baseline and increased during treatment in both groups (P < 0.001). However, trend analysis showed a greater (P < 0.01) increase in the osteoporotic women. These data do not support the hypothesis that defective osteoblast function is the major cause of bone loss in postmenopausal osteoporosis.

UR - http://www.scopus.com/inward/record.url?scp=0023227245&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023227245&partnerID=8YFLogxK

U2 - 10.1172/JCI112944

DO - 10.1172/JCI112944

M3 - Article

C2 - 3494046

AN - SCOPUS:0023227245

SN - 0021-9738

VL - 79

SP - 1249

EP - 1253

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

IS - 4

ER -

1,25-Dihydroxyvitamin D stimulation test for osteoblast function in normal and osteoporotic postmenopausal women

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this